Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials

INTRODUCTION: Temporary dose modifications, such as reductions or interruptions, may allow patients to better manage adverse events (AEs) associated with pirfenidone use and continue treatment for idiopathic pulmonary fibrosis (IPF). However, the impact of such dosing adjustments on efficacy and saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Nathan, Steven D, Lancaster, Lisa H, Albera, Carlo, Glassberg, Marilyn K, Swigris, Jeffrey J, Gilberg, Frank, Kirchgaessler, Klaus-Uwe, Limb, Susan L, Petzinger, Ute, Noble, Paul W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Interstitial Lung Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089326/
https://www.ncbi.nlm.nih.gov/pubmed/30116539
http://dx.doi.org/10.1136/bmjresp-2018-000323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089326/
https://www.ncbi.nlm.nih.gov/pubmed/30116539
http://dx.doi.org/10.1136/bmjresp-2018-000323

Ejemplares similares